Clinical trials: Crohn's Enteritis
Inflammatory Bowel Disease, Perianal Fistula
Perianal Fistula (PAF) Validation and Burden of Illness Study
The purpose of this study is to gain a better understanding of the disease burden and unmet need of perianal fistulas within Crohn's disease (CD) in Ontario.
- Conditions
- Inflammatory Bowel Disease, Perianal Fistula, Crohns Disease
- Trial name
- NCT03981939
- Testing
- No intervention
- Where
- Canada
- Volunteers
- 3,032 people
- Sponsor
- Takeda
Crohn's Disease
Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease
The purpose of this study is to determine Efficacy, Pharmacokinetics, and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease
- Trial name
- NCT00409682
- Testing
- Adalimumab
- Where
- 45 sites in United States, Belgium and 6 more
- Volunteers
- 192 people
- Sponsor
- Abbott
Crohn's Disease
Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine
The purpose of this study was intended to evaluate the long-term safety and effectiveness of adalimumab in participants with Crohn's disease (CD) who are treated as recommended in the product label.
- Trial name
- NCT01083680
- Volunteers
- 4,107 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Crohn's Disease, Inflammatory Bowel Disease
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
This study (UNITI-2) will compare the effects (both positive and negative) of an initial treatment with ustekinumab to a placebo over 8 weeks in patients with moderately to severely active Crohn's disease.
- Conditions
- Crohn's Disease, Inflammatory Bowel Disease, IBD, Colitis
- Trial name
- NCT01369342
- Testing
- Group 2 ustekinumab 130 mg, Group 3: ustekinumab approximately 6 mg/kg
- Where
- 220 sites in United States, Australia and 20 more
- Volunteers
- 640 people
- Sponsor
- Janssen Research & Development, LLC
Crohn's Disease, Spondyloarthritis
Imaging Biomarkers in Crohn's Associated Spondyloarthritis
In patients with Crohn's Disease, symptoms of inflammatory back pain (IBP) precede changes on plain X-rays by years, and MRI changes of axial inflammation precede development of X-ray changes.
- Trial name
- MaRCH-on (NCT02709694)
- Testing
- No intervention
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Hospital for Special Surgery, New York
Inflammatory Bowel Diseases
Safety and Tolerability Of Allogeneic Mesenchymal Stromal Cells in Pediatric Inflammatory Bowel Disease
In this trial, investigators will infuse donor bone marrow mesenchymal stromal cells intravenously, as a treatment for pediatric Crohn's disease or ulcerative colitis that has not responded to conventional therapies.
- Trial name
- NCT02150551
- Testing
- Allogeneic bone marrow-derived mesenchymal stromal cells
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Catherine Bollard
Crohn Disease
Ultrasound Evaluation of Crohn's Disease
The purpose of this study is to assess the effectiveness of a new ultrasound technology for evaluating Crohn's disease.
- Trial name
- NCT03235180
- Testing
- Sulfur Hexafluoride, Ultrasound Elastography, Ultrasound Vascularity
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Mayo Clinic
Crohn's Disease
Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease
The study will examine the safety and effectiveness of brodalumab for the treatment of moderate to severe Crohn's disease. Participants will randomly assigned to receive either brodalumab or placebo (a lookalike liquid that…
- Trial name
- NCT01150890
- Testing
- Brodalumab
- Where
- 50 sites in United States, Australia and 6 more
- Volunteers
- 130 people
- Sponsor
- Amgen
Crohn's Disease
A Study of E6011 in Participants With Active Crohn's Disease
The primary purpose of this study is to examine the efficacy and safety of E6011 at 12 weeks after administration by means of double-blind placebo-controlled trial.
- Trial name
- NCT03733314
- Testing
- E6011
- Where
- 46 sites in Czechia, Hungary and 3 more
- Volunteers
- 25 people
- Sponsor
- EA Pharma Co., Ltd.
Inflammatory Bowel Disease, Uterine Cervical Dysplasia
Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease
The Gardasil vaccine, a vaccine targeted towards the human papillomavirus (HPV), has been shown to prevent the transmission of several strains of HPV in young women.
- Trial name
- NCT01034358
- Testing
- Human Papillomavirus Vaccine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Crohn's Disease
A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease
A follow-on safety study in subjects with Crohn's Disease who have previously been withdrawn from the double-blind study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] due to an exacerbation of Crohn's Disease.
- Trial name
- PRECiSE 4 (NCT00160706)
- Testing
- Certolizumab Pegol (CDP870)
- Where
- 141 sites in United States, Australia and 22 more
- Volunteers
- 310 people
- Sponsor
- UCB Pharma SA
Crohn's Disease
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
This is a multi-centre, randomised, double-blind, active treatment, parallel group induction study in subjects with moderately-to-severely active Crohn's disease.
- Trial name
- SHIELD-4 (NCT01536418)
- Testing
- GSK1605786A
- Where
- 227 sites in United States, Australia and 29 more
- Volunteers
- 255 people
- Sponsor
- GlaxoSmithKline
Inflammatory Bowel Diseases (IBD), Crohn's Disease (CD)
Fecal Microbiota Transplantation in Pediatric Patients
A disturbance in the diversity of gut bacterial composition could be linked to several immune mediated diseases including inflammatory bowel diseases (IBD).
- Conditions
- Inflammatory Bowel Diseases (IBD), Crohn's Disease (CD), Ulcerative Colitis (UC)
- Trial name
- FMT (NCT02108821)
- Testing
- Fecal Microbiota Transplantation (FMT)
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Children's Mercy Hospital Kansas City
Crohn's Disease
Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's Disease
Objectives: The primary objective of the study was to determine the ability of ITF2357, administered orally at the dose of 50 mg b.i.d.
- Trial name
- CD (NCT00792740)
- Testing
- ITF2357
- Where
- 10 sites in Belgium, Italy and 1 more
- Volunteers
- 51 people
- Sponsor
- Italfarmaco
Ulcerative Colitis, Crohn's Disease
Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease
This was an open-label study to provide an opportunity for participants with Ulcerative Colitis (UC) who previously completed Study C13002 (NCT01177228), and for treatment-naïve participants with UC or Crohn's Disease (CD) to…
- Trial name
- NCT00619489
- Testing
- vedolizumab
- Where
- Canada
- Volunteers
- 72 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Crohn's Disease
Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease
The primary objective of this study was to demonstrate that tight control of disease activity, using stringent criteria based on Crohn's disease activity Index (CDAI), biomarkers (high sensitivity C-reactive protein [hs-CRP] and…
- Trial name
- CALM (NCT01235689)
- Testing
- Adalimumab, Prednisone, Azathioprine
- Volunteers
- 252 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Crohn's Disease
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
The primary purpose of this study was to determine the effect of vedolizumab induction treatment on clinical response and remission at 6 weeks and to determine the effect of vedolizumab maintenance treatment on clinical remission…
- Trial name
- GEMINI II (NCT00783692)
- Testing
- vedolizumab
- Where
- 114 sites in United States, Canada and 1 more
- Volunteers
- 1,116 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Crohn's Disease
Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD)
The purpose of this study is to evaluate the combined remission of complex perianal fistulas, defined as the clinical assessment at Week 24 of closure of all treated external openings that were draining at baseline despite gentle…
- Trial name
- ADMIRE-CD-II (NCT03279081)
- Testing
- Cx601
- Where
- 159 sites in United States, Belgium and 13 more
- Volunteers
- 568 people
- Sponsor
- Tigenix S.A.U.
Crohn's Disease
A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy
A medical research study in adult patients who have moderate to severe Crohn's disease designed to determine whether or not treatment with an experimental drug called ustekinumab (or CNTO1275) is safe or not and to determine if…
- Trial name
- NCT00771667
- Testing
- Ustekinumab 1mg/kg (IP), Ustekinumab 3 mg/kg (IP), Ustekinumab 6 mg/kg (IP)
- Where
- 174 sites in United States, Australia and 10 more
- Volunteers
- 526 people
- Sponsor
- Centocor, Inc.
Crohn's Disease
Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease
This study is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to examine the efficacy, safety, and pharmacokinetics of vedolizumab (MLN0002) in induction and maintenance therapy in…
- Trial name
- NCT02038920
- Testing
- Vedolizumab
- Where
- 56 sites in Japan
- Volunteers
- 157 people
- Sponsor
- Takeda